PTC 849200

Your search result can be sorted in ascending/descending order by clicking on the column headings, with the exception of Review Status/Past Decision(s).
* Please click on the DIN/PIN hyperlink to look up for more details of any group coverage(s) which may apply to that particular drug product.

Products Found: 36

MFR

Review Status/
Past Decision(s)

5-FLUOROURACIL
EFUDEX
50 MG / G
TOP  CRM
0.9006
N/A
G
NO

REGULAR BENEFIT

 

ACITRETIN
MINT-ACITRETIN
10 MG
ORL  CAP
1.2965
1.2965
CAP
YES

REGULAR BENEFIT

ACITRETIN
SORIATANE
10 MG
ORL  CAP
2.3069
1.2965
CAP
YES

REGULAR BENEFIT

 

ACITRETIN
TARO-ACITRETIN
10 MG
ORL  CAP
1.2965
1.2965
CAP
YES

REGULAR BENEFIT

ACITRETIN
MINT-ACITRETIN
25 MG
ORL  CAP
2.2770
2.2770
CAP
YES

REGULAR BENEFIT

ACITRETIN
SORIATANE
25 MG
ORL  CAP
4.0510
2.2770
CAP
YES

REGULAR BENEFIT

 

ACITRETIN
TARO-ACITRETIN
25 MG
ORL  CAP
2.2770
2.2770
CAP
YES

REGULAR BENEFIT

02337649
ALITRETINOIN
TOCTINO
30 MG
ORL  CAP
N/A
N/A
CAP
NO

NOT A BENEFIT *

AZELAIC ACID
FINACEA
15 %
TOP  GEL
0.6066
N/A
G
NO

REGULAR BENEFIT

BRODALUMAB
SILIQ
210 MG / SYR
INJ  NDL
N/A
N/A
SYR
NO

UNDER REVIEW *

CALCIPOTRIOL
DOVONEX
50 MCG / G
TOP  ONT
0.7837
N/A
G
NO

REGULAR BENEFIT

 

CALCIPOTRIOL MONOHYDRATE/ BETAMETHASONE DIPROPIONATE
DOVOBET
50 MCG / G * 0.5 MG / G
TOP  GEL
1.5210
N/A
G
NO

REGULAR BENEFIT

CALCIPOTRIOL MONOHYDRATE/ BETAMETHASONE DIPROPIONATE
DOVOBET
50 MCG / G * 0.5 MG / G
TOP  ONT
1.5477
N/A
G
NO

REGULAR BENEFIT

CALCIPOTRIOL MONOHYDRATE/ BETAMETHASONE DIPROPIONATE
ENSTILAR
50 MCG / G * 0.5 MG / G
TOP  FOA
1.5746
N/A
G
NO

REGULAR BENEFIT

02338572
CALCITRIOL
SILKIS
3 MCG / G
TOP  ONT
N/A
N/A
G
NO

NOT A BENEFIT *

COLLAGENASE
SANTYL
250 UNIT / G
TOP  ONT
3.0330
N/A
G
NO

REGULAR BENEFIT

IMIQUIMOD
ALDARA P
50 MG/G / G
TOP  CRM
52.2362
0.0000
G
YES

SPECIAL AUTHORIZATION

IMIQUIMOD
TARO-IMIQUIMOD PUMP
50 MG/G / G
TOP  CRM
43.4350
0.0000
G
YES

SPECIAL AUTHORIZATION

02400987
INGENOL MEBUTATE
PICATO
0.015 %
TOP  GEL
N/A
N/A
DOSE
NO

NOT A BENEFIT *

02400995
INGENOL MEBUTATE
PICATO
0.05 %
TOP  GEL
N/A
N/A
DOSE
NO

NOT A BENEFIT *

ISOTRETINOIN
ACCUTANE
10 MG
ORL  CAP
0.9547
0.9313
CAP
YES

REGULAR BENEFIT

 

ISOTRETINOIN
CLARUS
10 MG
ORL  CAP
0.9313
0.9313
CAP
YES

REGULAR BENEFIT

02396971
ISOTRETINOIN
EPURIS
10 MG
ORL  CAP
N/A
N/A
CAP
YES

NOT A BENEFIT *

02396998
ISOTRETINOIN
EPURIS
20 MG
ORL  CAP
N/A
N/A
CAP
NO

NOT A BENEFIT *

02397005
ISOTRETINOIN
EPURIS
30 MG
ORL  CAP
N/A
N/A
CAP
NO

NOT A BENEFIT *

ISOTRETINOIN
ACCUTANE
40 MG
ORL  CAP
1.9480
1.9003
CAP
YES

REGULAR BENEFIT

 

ISOTRETINOIN
CLARUS
40 MG
ORL  CAP
1.9003
1.9003
CAP
YES

REGULAR BENEFIT

02397013
ISOTRETINOIN
EPURIS
40 MG
ORL  CAP
N/A
N/A
CAP
YES

NOT A BENEFIT *

IXEKIZUMAB
TALTZ
80 MG / SYR
INJ  NDL
1582.2369
N/A
SYR
NO

SPECIAL AUTHORIZATION

IXEKIZUMAB
TALTZ AUTOINJECTOR
80 MG / SYR
INJ  NDL
1582.2369
N/A
SYR
NO

SPECIAL AUTHORIZATION

02323273
METHYL AMINOLEVULINATE HYDROCHLORIDE
METVIX
16.8 %
TOP  CRM
N/A
N/A
G
NO

NOT A BENEFIT *

02247238
PIMECROLIMUS
ELIDEL
1 %
TOP  CRM
N/A
N/A
G
NO

NOT A BENEFIT *

 

TACROLIMUS
PROTOPIC
0.03 %
TOP  ONT
2.2601
N/A
G
NO

SPECIAL AUTHORIZATION

TACROLIMUS
PROTOPIC
0.1 %
TOP  ONT
2.3993
N/A
G
NO

SPECIAL AUTHORIZATION

TAZAROTENE
TAZORAC
0.05 %
TOP  GEL
1.3886
N/A
G
NO

REGULAR BENEFIT

 

TAZAROTENE
TAZORAC
0.1 %
TOP  GEL
1.3886
N/A
G
NO

REGULAR BENEFIT

 


To return to the printable Drug Benefit List and related publications, click here.

Last Updated: null

NOTICE:
The DBL, DBS and related publications require knowledgeable interpretation and are intended primarily for professional health care practitioners, pharmacies, hospitals and organizations associated with the manufacture, distribution and use of pharmaceutical preparations.

Electronic versions of all DBL and DBS related publications are unofficial versions and are provided for convenience and private use only. Official paper versions can be obtained from Alberta Blue Cross who publishes them on behalf of Alberta Health and Alberta Human Services.

Alberta Health reserves the right to make changes, without notice, to the List through the Interactive DBL(iDBL), and any such changes to the Interactive DBL(iDBL) are effective the date of the change (unless otherwise stated) and regardless of the date of publication in the paper version or updates.